ClinicaliQ Trial Snapshot
- Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study — Recruiting • Phase II • NCT06914908.
- Long-term safety and efficacy study of lunsekimig (a new treatment) in adults with poorly controlled chronic rhinosinusitis with nasal polyps over 52 weeks.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study duration will be up to approximately 56 weeks per participant, 52 weeks of treatment period, and 4 weeks of follow-up. Conditions: Chronic Rhinosinusitis With Nasal Polyps Interventions: lunsekimig, Mometasone furoate nasal spray (MFNS) Lead Sponsor: Sanofi Planned Enrollment: 64 participants